Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Topical ruxolitinib cream may help treat frontal fibrosing alopecia.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Deucravacitinib effectively treats psoriasis and may help with other skin conditions.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.

Accurate diagnosis and personalized treatment are crucial in dermatopathology.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.

Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

Dupilumab helped a 4-year-old grow hair back after another treatment failed.

Baricitinib is effective in promoting hair growth in severe alopecia areata.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.